Loading search results
Sponsor study identifier
observational
83
1 country
7
Study Start
September 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2009
Actual (reported)Study Completion
December 2009
Actual (reported)Justification: We have recently demonstrated that maternofetal alloimmunization was not limited to blood cells: maternal alloimmunization against a glomerular podocyte antigen expressed by the placenta can induce neonatal membranous glomerulonephritis. Early recurrent pregnancy losses, preeclampsia and intervillositis are obstetrical pathologies which share an anomaly of placentation. Pathophysiology of these diseases is not yet fully understood; nevertheless the hypothesis of an incompatibility between mother and child is often mentioned. The aim of this project is to detect and study the cases of recurrent pregnancy losses, preeclamspia and intervillositis which could be induced by tissular maternofetal alloimmunization. Materials and methods: Patients suffering from recurrent pregnancy losses of unknown origin, preeclamspia or intervillositis will be included in this project. Mothers' sera will be studied by indirect immunofluorescence and Western Blot on placental biopsies from different origins and gestational ages. This stage will enable us to detect possible maternal allo-antibodies. After detecting and revealing antibodies, nature of the target antigen will be identified by immunoprecipitation of placental extracts, using the positive sera. Immunoprecipitation will be followed by a mass spectrometry analysis of detected proteins. Expected results: This study will enable us:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2009
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2006
Date type not reportedThis date has not been verified as actual or estimated.
April 3, 2007
Actual (reported)April 4, 2007
Actual (reported)July 2009
Actual (reported)December 2009
Actual (reported)60 womens for repeated miscarriages will be included
70 women for pre-eclampsia will be included
20 women for intervillites will be included
Neonatal pathologies can be caused by an alloimmunisation maternal fetal tissue, it's conceivable that certain pathologies. Obstetrics may be part of the same mechanism. Among these pathologies placentaires, for whom a "maternal-fetal incompatibility" is often mentioned, could be secondary to tissue alloimmunization against antigens independent of the immune system
Bordeaux University Hospital
Bordeaux, 33076, France
LIMOGES University Hospital
Limoges, 87042, France
Saint Antoine Hospital
Paris, 75012, France
Tenon Hospital
Paris, 75020, France
Trousseau Hospital
Paris, 75571, France
South Reunion Hospital
Saint-Pierre, 97448, France
Toulouse University Hospital
Toulouse, 31059, France
Vincent GUIGONIS, MD
University Hospital, Limoges
83 participants (actual enrollment reported by the registry).
First Submitted
April 3, 2007
First Posted
April 4, 2007
Study Start
September 2006
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
July 2009
Actual (reported)Study Completion
December 2009
Actual (reported)Last Updated
August 13, 2018
Record last verified: 2009-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: